Cancer screening company Nucleix raises 2.5 milion euros
Founded in 2008, Nucleix develops urine and blood-based non-invasive, molecular cancer screening tests. Israel-based Nucleix Ltd. has received 2.5 million euros in funding from Horizon 2020, the European Union’s research and innovation program, to develop its blood-based lung cancer early detection test, the company announced Monday. Nucleix received a grant of an undisclosed amount from the program in 2016.
Subscription Confirmation Required
Go to your email inbox
Go to the inbox of the email
address you just used to sign up.
Open the confirmation email
Find the email sent by us. It has the subject line
“Nucleix: Please Confirm Subscription” and I
sent from “[email protected]”.
Click the confirmation link
Click on the link inside the
email and you’re good to go.